

SPEXIS AG CHF0.02

ISIN: CH0106213793 WKN: 10621379 Asset Class: Stock

Company

2024/07/09 09:08:05

Price

0.08 CHF

Difference ▲ 14.71%(0.01)

Contact Details

SPEXIS LTD.

Tel: +41-61-567-16-00

--


Fax: +41-61-567-16-01

Hegenheimermattweg 125

Web: <http://spexisbio.com>

4123 Allschwil

E-mail: info@spexisbio.com



Company Profile

Spexis Ltd. is a clinical-stage biopharmaceutical company, which engages in the research, development, and commercialization of respiratory therapeutics. The firm focuses on rare, chronic respiratory diseases (CRD) and chronic lung infections in cystic fibrosis. Its product pipeline includes ColiFin, Inhaled Murepavadin, Balixafortide (POL6326), OMPA, EBX-002, and POL6014 (Lonodelestat). The company was founded by Daniel Obrecht and Jean-Pierre Obrecht in 1996 and is headquartered in Allschwil, Switzerland.

Financial figures, Fiscal year: from 01.01. to 31.12.

Financial figures	2023		2022		2021	
	Assets	Liabilities and equity	Assets	Liabilities and equity	Assets	Liabilities and equity
Current assets	3,286,000		3,087,000		18,295,000	
Common stock capital		1,179,000		975,000		951,000
Fixed assets	13,491,000		26,863,000		31,601,000	
Equity capital of a company		2,287,000		19,401,000		30,223,000
Cash and cash equivalents	511,000		1,804,000		14,368,000	
Accrued liabilities		-		0		4,180,000
Other assets	-		-		-	
Current liabilities		8,714,000		6,002,000		9,845,000
Prepayments and accrued income	-		-		-	
Non-current liabilities		5,775,000		4,547,000		9,827,000
Different income		-		-		-
Other liabilities		0		0		0
Total assets	16,777,000	16,777,000	29,951,000	29,951,000	49,897,000	49,897,000

Balance notes

	2023	2022	2021
Accounting standard	IFRS	IFRS	IFRS
Employees	-	28	50
Equity ratio	13.64%	64.78%	60.79%
Debt-equity ratio	633.36%	54.37%	64.51%

Others

	2023	2022	2021
Tax Expense Rate	0.00%	0.00%	0.00%

SPEXIS AG CHF0.02

ISIN: CH0106213793 WKN: 10621379 Asset Class: Stock

Income statement

	2023	2022	2021
Turnover	0	0	0
Net income	-19,618,000	-18,553,000	-11,861,000
EBIT	-19,376,908	-18,910,799	-10,706,720
Operating income before taxes	-19,618,000	-18,553,000	-11,861,000
Cash Flow	-	-12,118,000	-1,149,000
Net interest income	-762,000	-150,000	-1,442,000
Research and development expenses	12,232,000	9,768,000	875,000
Income taxes	-	0	0
Result from investments in subsidiaries, associates and other	-	0	0
Revenues per employee	-	0	0

Board of Directors

Dan Hartman	Member of the administrative board
Dennis Ausiello	Member of the administrative board
Kuno Sommer	Member of the administrative board
Robert Clarke	Member of the administrative board
Bernard Bollag	Member of the administrative board

Members of Management Board

Jeffrey D. Wager	Chairman of Managing Board
Jürgen Fröhlich	Member of Executive Committee